Biotech company SeekIn Inc announced on Monday that a new study published in the Journal of Molecular Diagnostics reports the successful clinical validation of SeekInCare, a novel, non-invasive multi-omics blood test designed for the early detection of multiple cancer types.

SeekInCare integrates advanced genomic, epigenetic and proteomic analyses to identify cancer at its early stage. It uses shallow whole-genome sequencing of cell-free DNA (cfDNA) and measures seven protein tumour markers from 8ml peripheral blood. The test analyses multiple cancer hallmarks, including copy number aberration, fragment size, end motif and oncogenic virus, combined with artificial intelligence algorithms.